Request a Quote |

Cyprotex appoints Dr Rob Elsby as Leader of Drug Transporter Team

Cyprotex PLC (AIM: CRX), a specialist ADME-Tox Contract Research Organisation (CRO), today announces the appointment of Dr Rob Elsby as Leader of its Drug Transporter Team. Dr Elsby is a recognised expert in the drug transporter field, as exemplified by his numerous publications including co-authoring an International Transporter Consortium (ITC) whitepaper. These publications span such areas as the validation of in vitro transporter assays, predicting clinical DDI exposure changes for statins, and the role that transporter pharmacogenetics play in mediating ethnic differences in statin exposure. Dr Elsby’s role at Cyprotex will involve leading the strategic direction of Cyprotex’s transporter based assays both in terms of new research and its client-based services.

Prior to joining Cyprotex, Dr Elsby worked within a DMPK (Drug Metabolism and Pharmacokinetics) function at AstraZeneca where, over a period of 11 years, he helped develop the internal drug transporter scientific capability both practically and strategically. During this time his expert knowledge and technical interpretation of drug transporter science was routinely used towards the provision of drug disposition and clinical DDI (drug-drug interaction) risk understanding to global discovery and development project teams.

Dr Elsby will be presenting new research performed at Cyprotex in the field of transporters at the AAPS/ITC Joint Workshop on Drug Transporters in Baltimore, USA in April 2015. The research focuses on the impact of inhibitor pre-incubation time on uptake transporter interactions in vitro.

On joining Cyprotex, Dr Elsby said “I am very excited to be joining a leading scientific team that can utilise its specialist services/expertise to fully integrate in vitro ADME, transporter and toxicity data with PBPK (physiologically based pharmacokinetic) modelling approaches towards obtaining a more holistic prediction of a molecule’s safety profile in humans.”

Dr Anthony Baxter, Cyprotex’s Chief Executive Officer said, “We are delighted to welcome Dr Elsby to our scientific team. Rob’s experience in the extrapolation of in vitro drug transporter interactions to the clinical situation will be vital in assisting our customers in understanding the relevance of the data generated. Through expansion of its transporter capabilities, Cyprotex can now offer the full range of in vitro assays for regulatory DDI (drug-drug interaction) packages.”

For further information:

Cyprotex PLC 
Tel: +44 (0) 1625 505 100
Dr Anthony Baxter, Chief Executive Office
John Dootson, Chief Financial Officer
Mark Warburton, Chief Operating Officer and Legal Counsel

N+1 Singer (Nomad and broker to Cyprotex)
Tel: +44 (0)20 7496 3000
Shaun Dobson
Jen Boorer

Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 900 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services, extending from early drug discovery through to IND submission. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries.  The Company’s core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr® toxicity prediction technology, predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see

Contact us

News categories


Contact us to discuss your ADME Tox issues or request a quote

North America (East Coast): +1-888-297-7683
Europe: +44 (0)1625 5051000


or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

By clicking on ‘Send’ I agree that my data is being transferred and used by Cyprotex and the affiliated Evotec Group. The Evotec Group currently consists of the following companies. For further details please see our privacy policy.

If you would like to be kept informed of our latest services, new research, events and other news please tick the box below: